Refocus Group, Inc.

Refocus Group, Inc.

RFCS

RFCSRefocus Group, Inc. US flag

Other OTC

0.00

USD

- -

- -

25.00Market Cap

Refocus Group, Inc.

RFCS

(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Lifecare AS (LIFE.OL)
Misonix, Inc. (MSON)
Universus Photo Imagings Limited (UNIVPHOTO.BO)
Ion Beam Applications S.A. (IOBCF)
Drägerwerk AG & Co. KGaA (DGWPF)
4DMedical Limited (4DX.AX)
Business: Refocus Group, Inc. is a medical device company specializing in the research, development, and commercialization of treatments for human vision disorders, with a primary focus on presbyopia. The company offers the VisAbility™ Micro Insert System, an innovative investigational medical device designed to improve near vision correction by providing a binocular presbyopic treatment that works outside the visual axis, aimed at reducing or eliminating the need for reading glasses. The device is currently approved for sale in the European Union and is undergoing clinical trials in the United States. Founded in 2006 and headquartered in Dallas, Texas, Refocus Group serves the global ophthalmology market through its development of surgical vision correction products. The company targets patients experiencing presbyopia, offering a novel surgical solution to address age-related near vision loss. Recent major developments include Refocus Group securing $15 million in funding from investors such as WP Global Partners and MedCare Investment Funds to advance its clinical and regulatory activities. The company continues to expand the clinical adoption of its VisAbility™ Micro Insert System with ongoing strategic partnerships with ophthalmology practices to support patient access. Refocus Group remains focused on obtaining regulatory approvals and commercialization of its products to establish itself as a surgical standard of care for presbyopia. Separately, it is important to distinguish that "ReFocus Eye Health," a distinct entity operating as a management services organization supporting a network of ophthalmology and retina practices across multiple U.S. states, has recently expanded its geographic footprint through acquisitions and partnerships, including the acquisition of OptiCare Eye Health & Vision Centers and partnerships with leading retina practices in the Northeast. These expansions enhance their comprehensive eye care service offerings but are unrelated to Refocus Group, Inc., the medical device company. In summary, Refocus Group, Inc. is a Dallas-based medical device innovator focusing on presbyopia surgical treatments through its VisAbility™ Micro Insert System, supported by recent funding and ongoing clinical development to commercialize its technology in key global markets.

Company News